EGFR and neutropenia: However, while the successful rate of combination Gem plus erlotinib is strictly dependent on the EGFR status and other potential signatures (Hoyer et al., 2021), serious side effects have been reported in PDAC patients treated with Gem plus nab-paclitaxel, including neutropenia, peripheral neuropathy, and fatigue (Blomstrand et al., 2019).